Immunotoxicity of multiple dosing regimens of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.

We have shown that doxorubicin entrapped in cardiolipin liposomes retain antitumour efficacy in mice but had diminished cardiac uptake and cardiotoxicity. Such liposomes are preferentially taken up by spleen. In a previous study we showed that a single dose of liposomal doxorubicin is not more toxic than free doxorubicin with regard to immunologic parameters including generation of cytotoxicity for histocompatibility alloantigens and mitogenic responsiveness. In the present study, we have explored clinically relevant multiple dosing at weekly intervals, 2, 3, or 4 times. Again, despite splenic localization of liposomal doxorubicin, the depressive effect on these immunological parameters is not greater than the effect of free drug, and, in addition, the damage is repaired earlier.

• Publication year

  1986

• Venue

  British Journal of Cancer

• Publication date

  1986-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/bjc.1986.190PMID 3489480PMCID 2001633
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative immunotoxicity of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes

  2004cited by this paper
• Antitumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes

  2004cited by this paper
• Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes.

  1985cited by this paper
• Potential of liposomes to ameliorate anthracycline-induced cardiotoxicity.

  1984cited by this paper
• Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-O-stearoyl-N-acetylmuramyl-L-α-aminobutyryl-D-isoglutamine

  1984cited by this paper
• Pharmacokinetic and therapeutic consequences of liposomal drug delivery: Fluorodeoxyuridine and Amphotericin B as examples

  1983cited by this paper
• Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation.

  1983cited by this paper
• Preliminary observations of immunomodulatory activity of lymphoblastoid interferon-alpha administered every other day or weekly.

  1983cited by this paper
• Cancer : Principles and Practice of Oncology

  1982cited by this paper
• Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice.

  1982cited by this paper
• Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration.

  1982cited by this paper
• Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes.

  1982cited by this paper
• Modulation of antitumoral antibody-dependent cellular cytotoxicity and natural killer activity by Adriamycin and daunorubicin

  1982cited by this paper
• Lymphatic absorption and tissue disposition of liposome-entrapped [14C]adriamycin following intraperitoneal administration to rats.

  1981cited by this paper
• Effects of adriamycin on the activity of mouse natural killer cells.

  1980cited by this paper
• Role of host defense merchanisms in the antitumor activity of adriamycin and daunomycin in mice.

  1979cited by this paper
• In vitro and in vivo studies with adriamycin liposomes.

  1979cited by this paper
• PHARMACOKINETICS OF LIPOSOME‐ENCAPSULATED ANTITUMOR DRUGS AND IMPLICATIONS FOR THERAPY *

  1978cited by this paper
• Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin.

  1978cited by this paper
• Targeting of drugs

  1977cited by this paper
• Fate of a liposome-associated agent injected into normal and tumour-bearing rodents. Attempts to improve localization in tumour tissues.

  1977cited by this paper
• Adriamycin cardiotoxicity in man.

  1974cited by this paper
• Treatment of Ewing's sarcoma with adriamycin (NSC-123127).

  1972cited by this paper
• Clinical trials with adriamycin

  1971cited by this paper
• On the immunodepressive action of adriamycin

  1971cited by this paper
• Phase I and preliminary phase II evaluation of adriamycin (NSC 123127).

  1970cited by this paper

• Liposomal Doxorubicin, but Not Platinum-Taxane, Supports MHC-II Expression and Immune Maturation in the Ovarian Tumor Microenvironment

  2025cites this paper
• Cardiolipin nanodisks confer protection against doxorubicin-induced mitochondrial dysfunction.

  2022cites this paper
• Gold Nanorod/Reduced Graphene Oxide Composite Nanocarriers for Near-Infrared-Induced Cancer Therapy and Photoacoustic Imaging

  2021cites this paper
• Dye binding assay reveals doxorubicin preference for DNA versus cardiolipin.

  2020cites this paper
• A matter of life or death : autophagy in the context of prolonged doxorubicin therapy

  2019cites this paper
• Liposomes with cyclic RGD peptide motif triggers acute immune response in mice

  2019cites this paper
• Non-immunogenic, low-toxicity and effective glioma targeting MTI-31 liposomes.

  2019cites this paper
• Toxicity Concerns of Nanocarriers

  2017cites this paper
• Reduced Graphene Oxide Nanosheet for Chemo-photothermal Therapy.

  2016cites this paper
• Furanodiene enhances the anti-cancer effects of doxorubicin on ERα-negative breast cancer cells in vitro.

  2016cites this paper
• PREPARATION OF CHEMICAL AND PHYSICAL CONJUGATES OF SELF-ASSEMBLING NANOPARTICLES WITH CELL-PENETRATING PEPTIDE AND DOXORUBICIN

  2015cites this paper
• Folate conjugated silk fibroin nanocarriers for targeted drug delivery.

  2014cites this paper
• Preparation and characterization of glycol chitin as a new thermogelling polymer for biomedical applications.

  2013cites this paper
• Quartz crystal microbalance monitoring of intervention of doxorubicin-loaded core–shell magnetic silica nanospheres on human breast cancer cells (MCF-7)

  2012cites this paper
• Evaluation of triblock copolymeric micelles of δ- valerolactone and poly (ethylene glycol) as a competent vector for doxorubicin delivery against cancer

  2011cites this paper
• New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: Part I--Formulation development and in-vitro characterization.

  2010cites this paper
• Chitosan micro- and nanospheres: fabrication and applications for drug and DNA delivery.

  2009cites this paper
• Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy.

  2009cites this paper
• Injectable chitosan hydrogels for localised cancer therapy.

  2008cites this paper
• Synthesis of sol-gel mesoporous silica materials providing a slow release of doxorubicin

  2007cites this paper
• Novel drug delivery system using thermoreversible gelation polymer for malignant glioma

  2006cites this paper
• Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes

  2004cites this paper
• Sterically Stabilized Etoposide Liposomes: Evaluation of Antimetastatic Activity and Its Potentiation by Combination with Sterically Stabilized Pentoxifylline Liposomes in Mice

  2003cites this paper
• Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier.

  2001cites this paper
• Chemotherapy in advanced prostate cancer.

  1999cites this paper
• Loading of doxorubicin into liposomes by forming Mn2+-drug complexes.

  1998cites this paper
• Toxicity of doxorubicin entrapped within long-circulating liposomes

  1997cites this paper
• Liposomal doxorubicin‐induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages

  1995cites this paper
• Clinical Evaluation of Liposome Encapsulated Doxorubicin and the Modulation of Multidrug Resistance in Cancer Cells

  1994cites this paper
• Modulation of Multidrug Resistance in Cancer Cells by Liposome Encapsulated Doxorubicin

  1994cites this paper
• Liposomes in the treatment of malignancy: a clinical perspective.

  1992cites this paper
• Preparation and characterization of polymer coated small unilamellar vesicles.

  1991cites this paper
• A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin.

  1990cites this paper
• Use of liposomes as injectable-drug delivery systems.

  1989cites this paper
• Liposomes in cancer therapy

  1989cites this paper
• Liposomes as a drug delivery system: optimization studies.

  1988cites this paper